Susquehanna International Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Susquehanna International Group’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-855	Closed	-$36K	–	14226
2022 Q3	$36K	Buy	855 +115	+16%	+$5.26K	﹤0.01%	12389
2022 Q2	$31K	Buy	740 +95	+15%	+$4.4K	﹤0.01%	12214
2022 Q1	$44K	Sell	645 -5,080	-89%	-$423K	﹤0.01%	12364
2021 Q4	$695K	Sell	5,725 -2,060	-26%	-$348K	﹤0.01%	8285
2021 Q3	$1.1M	Buy	7,785 +5,640	+263%	+$1.12M	﹤0.01%	7314
2021 Q2	$589K	Buy	+2,145	New	+$541K	﹤0.01%	9202

Other funds holding EVLO

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Susquehanna International Group's EVLO Position: Q4 2023 in Review

Susquehanna International Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 26,679 shares — an estimated $105K sold.

Susquehanna International Group first reported a position in EVLO in Q3 2020 and held it in 7 quarters. The position peaked at $687K in Q1 2022. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

Susquehanna International Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Susquehanna International Group sold 26,679 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $105K.
Susquehanna International Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Susquehanna International Group's Evelo Biosciences, Inc. Common Stock position peaked at $687K in Q1 2022.
2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.